Target intelligence / Profile preview

MIF antisense RNA 1 (MIF-AS1)

Target
MIF-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA, Other (non-protein coding RNA)
01

Overview

MIF antisense RNA 1 (MIF-AS1) is a long non-coding antisense RNA, located on chromosome 21 or possibly 22 (some sources disagree), with emerging evidence of a critical role in regulating gene expression in cancer and inflammatory contexts[1]. MIF-AS1 acts as a molecular sponge for microRNAs such as miR-212-5p, thereby upregulating target genes like NDUFA4, which promote tumor cell proliferation and suppress apoptosis by modulating mitochondrial oxidative phosphorylation[3]. Its expression is notably increased in certain cancers, including gastric cancer. MIF-AS1 exemplifies the significance of lncRNAs as regulators of key biological processes and as potential therapeutic targets, though no clinical drugs directly target it yet. The molecule is under active study as both a biomarker and a molecular target due to its influence on cellular pathways central to disease progression[1][3][5].

Other names
MIF-AS1LOC284889MIF-AS
02

Mechanism of action

Molecular sponge for microRNAs (miR-212-5p, miR-29a-3p) that regulate genes such as NDUFA4. Competitive endogenous RNA (ceRNA) function, modulating mRNA stability and translation.

03

Biological functions

Regulation of gene expressionModulation of cell proliferationPromotion of cell survival by inhibiting apoptosisInfluences immune response and inflammation
04

Disease associations

Cancer, especially gastric cancerInflammationImmune dysregulationPotential roles in other disease contexts require further research
05

Safety considerations

No direct safety concerns documented to date, but therapeutic manipulation of lncRNAs can affect fundamental pathways in proliferation, apoptosis, and immune regulation, potentially leading to off-target effects or altered disease progression.
06

Biomarkers

Upregulation (expression level) of MIF-AS1 in tumor tissues (notably gastric cancer) may serve as a biomarker for diagnosis or prognosisAssociated upregulation of NDUFA4 can be monitored

Beyond the preview

Go deeper on MIF antisense RNA 1 (MIF-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIF antisense RNA 1 (MIF-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call